Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey Kim

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Julia A Beaver, W David McGuinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
JAMA Network Open|April 12, 2024
Remote Monitoring and Data Collection for Decentralized Clinical TrialsBobby Daly, Otis W Brawley, Mary K Gospodarowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 14, 2016
FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast CancerAmanda J Walker, Suparna Wedam, Laleh Amiri-Kordestani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2015
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast CancerJulia A Beaver, Laleh Amiri-Kordestani, Rosane Charlab, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 19, 2015
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Gwynn Ison, Amy E McKee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2016
FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These DrugsGwynn Ison, Julia A Beaver, W David McGuinn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2014
FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutationGeoffrey Kim, Amy E McKee, Yang-Min Ning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 6, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summaryKatherine Thornton, Geoffrey Kim, V Ellen Maher, et al.
JAMA Network Open|April 12, 2024
Remote Monitoring and Data Collection for Decentralized Clinical TrialsBobby Daly, Otis W Brawley, Mary K Gospodarowicz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation-Associated Advanced Ovarian CancerSanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, et al.
Pageof 3